Immune checkpoint inhibitors (ICIs) antagonize inhibitory receptors and ligands that mediate T-cell activity, like the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein 1 and its ligand (PD-1/PD-L1), and lymphocyte-activation gene 3 (LAG-3), thus promoting tumor-specific immune response, but also potentially triggering immune-related adverse events (irAEs) (Waldman et al., 2020). Here, PDCD1 is linked to neoplasm.